Research Radartracking 2 published studies · 1 clinical trials · 2 cancer pages · updated Jun 2026Open the Research Map →

Ovarian Rhabdomyosarcoma

An ultra-rare ovarian sarcoma with skeletal-muscle differentiation. Management borrows from soft-tissue/rhabdomyosarcoma playbooks plus ovary-specific surgical principles.

Educational only: This page is not medical advice. Coordinate decisions with your oncology team.

Reviewed Jun 2026 · site editor · How we review →

AI extractedhuman reviewedsources checkedretractions suppressed· last updated Jun 2026

Evidence at a glanceInsufficient evidenceReported positive
2 published studies that name Ovarian Rhabdomyosarcoma0 human studies (trial, observational, or meta-analysis)18 source documents in the Ovarian Rhabdomyosarcoma corpus

last checked June 8, 2026

Why this grade?

Insufficient evidence — No primary experimental studies yet.

Computed deterministically from the studies’ types and reported outcomes — not written by AI, and not a claim that anything works.

Treatment map: Ovarian Rhabdomyosarcoma

Open as a full page →

Standard care plus every compound studied in the literature (each cited) and graded by evidence, organized by clinical readiness. A category, not a verdict that anything works — confirm anything here with your oncology team.

59
Interventions
46
Standard of care
0
Tested in people
1
Lab / animal
8
Named in lit.
6
Classes
Standard of care (46) Guideline option (4) Tested in people (0) Lab / animal only (1) Named in the literature (8)
Clinical evidence
Preclinical evidence
Standard of care
Guideline option
Tested in people
Lab / animal only
Named in the literature
Surgery & procedures
10
—
—
—
2
Radiotherapy
8
—
—
—
2
Chemotherapy
18
—
—
—
4
Targeted therapy
9
3
—
—
—
Immunotherapy
1
1
—
—
—
Other
—
—
—
1
—

Columns group into clinical evidence (used in, or tested on, people) and preclinical evidence (lab/animal, or only named in the literature). Cell = number of interventions; a dashed cell means none recorded there.

Established care — detail (50)
Surgery & procedures
Aim for complete macroscopic resection when feasible
Aim for complete macroscopic resection when feasible.
CurativeStandardCurated
Unilateral salpingo-oophorectomy often required
Unilateral salpingo-oophorectomy often required; hysterectomy/contralateral oophorectomy based on age, stage, and fertility goals.
CurativeStandardCurated
Nodal evaluation considered, especially for alveolar RMS given higher…
Nodal evaluation considered, especially for alveolar RMS given higher nodal risk.
CurativeStandardCurated
Fertility-sparing approaches only in highly selected early cases with…
Fertility-sparing approaches only in highly selected early cases with multidisciplinary input.
CurativeStandardCurated
Plan en-bloc resection to avoid capsular rupture or tumor spill
Plan en-bloc resection to avoid capsular rupture or tumor spill; use a specimen bag for extraction to limit peritoneal seeding.
CurativeStandardCurated
Mark close/deep margins with clips to guide adjuvant radiation planning
Mark close/deep margins with clips to guide adjuvant radiation planning.
CurativeStandardCurated
If an unplanned (‘whoops’) resection occurred, restage and consider r…
If an unplanned (‘whoops’) resection occurred, restage and consider re-excision to achieve R0 before RT.
CurativeStandardCurated
In bulky disease, consider neoadjuvant chemotherapy to downstage befo…
In bulky disease, consider neoadjuvant chemotherapy to downstage before definitive surgery.
CurativeStandardCurated
For oligometastatic disease, discuss metastasectomy or ablation (lung…
For oligometastatic disease, discuss metastasectomy or ablation (lung/liver) in tumor board after systemic control.
CurativeStandardCurated
Coordinate ureteral stents or bowel resection with peri-chemo timing…
Coordinate ureteral stents or bowel resection with peri-chemo timing to minimize infectious complications.
CurativeStandardCurated
Radiotherapy
Consider for positive margins, nodal involvement, or unresectable/loc…
Consider for positive margins, nodal involvement, or unresectable/local recurrence.
—StandardCurated
Pelvic RT planning must balance organ tolerance and prior surgeries
Pelvic RT planning must balance organ tolerance and prior surgeries.
—StandardCurated
SBRT
SBRT can be considered for oligometastatic lung/bone disease.
Advanced / metastaticStandardCurated
Use IMRT/VMAT to spare bowel, bladder, rectum, and ovaries/uterus whe…
Use IMRT/VMAT to spare bowel, bladder, rectum, and ovaries/uterus when organ preservation matters.
—StandardCurated
Post-op RT
Post-op RT is guided by margin status (R1/R2) and nodal disease; pre-op RT is an option for downstaging in select cases.
—StandardCurated
Spine/bone mets: consider SBRT for pain control and local control
Spine/bone mets: consider SBRT for pain control and local control; screen for cord compression symptoms.
—StandardCurated
Time RT around systemic therapy to minimize overlapping toxicities (e
Time RT around systemic therapy to minimize overlapping toxicities (e.g., ifosfamide renal, anthracycline cardiac).
—StandardCurated
Lung mets: SBRT or wedge resection discussed case-by-case after syste…
Lung mets: SBRT or wedge resection discussed case-by-case after systemic response.
—StandardCurated
Chemotherapy
VAC-based regimens (vincristine, actinomycin, cyclophosphamide) stand…
VAC-based regimens (vincristine, actinomycin, cyclophosphamide) standard in pediatric/AYA RMS.
—StandardCurated
Adult options
Adult options include doxorubicin/ifosfamide or gemcitabine/docetaxel (extrapolated from soft-tissue sarcoma).
—StandardCurated
Platinum/taxane regimens
Platinum/taxane regimens are not standard for pure RMS unless mixed histology is present.
—StandardCurated
Clinical trial enrollment strongly encouraged due to rarity
Clinical trial enrollment strongly encouraged due to rarity.
—StandardCurated
Risk-adapted intensity with early response assessment (typically after 2
Risk-adapted intensity with early response assessment (typically after 2–3 cycles); switch or escalate if inadequate response.
—StandardCurated
Consider VAC/IVA variants or VDC/IE-style intensity in AYA/fit adults…
Consider VAC/IVA variants or VDC/IE-style intensity in AYA/fit adults when tolerated—individualize to comorbidity and goals.
—StandardCurated
Anthracycline cardioprotection (dexrazoxane) and dose-capping strategies
Anthracycline cardioprotection (dexrazoxane) and dose-capping strategies may preserve intensity over longer courses.
—StandardCurated
Ifosfamide protocols: ensure mesna, aggressive hydration, and CNS/ren…
Ifosfamide protocols: ensure mesna, aggressive hydration, and CNS/renal monitoring (encephalopathy, proximal tubulopathy).
—StandardCurated
Maintenance concepts (e.g., low-dose alkylator/vinca)
Maintenance concepts (e.g., low-dose alkylator/vinca) are investigational in adults—prefer within trials.
MaintenanceStandardCurated
VAC (vincristine/actinomycin/cyclophosphamide) (pediatric/AYA)
Foundation for pediatric RMS; adult tolerance varies. Use growth-factor prophylaxis; early response check at 2–3 cycles to decide on escalation or switch.
—StandardCurated
Doxorubicin/Ifosfamide variants (adult STS)
Common adult sarcoma backbone; monitor cardiac/renal toxicity. Consider dexrazoxane for cardioprotection; strict mesna/hydration and CNS/renal monitoring for ifosfamide.
—StandardCurated
Gemcitabine/Docetaxel (recurrent/palliative)
Soft-tissue sarcoma option; activity varies in RMS. Useful for symptom control and disease stabilization when curative options are limited.
Advanced / metastaticStandardCurated
VDC/IE (vincristine/doxorubicin/cyclophosphamide ↔ ifosfamide/etoposi…
Intensified alternating regimen; consider for bulky/biologically adverse disease to enable resection. Requires G-CSF, cardioprotection strategy, and tight toxicity monitoring.
—StandardCurated
IVA (ifosfamide/vincristine/actinomycin) (neoadjuvant/anthracycline-a…
Option when avoiding anthracyclines (cardiac risk) or as bridge to surgery; ensure mesna/hydration and neuro/renal surveillance.
NeoadjuvantStandardCurated
VIT (vincristine/irinotecan/temozolomide) (relapsed/chemo-pretreated)
Pediatric-relapse–derived; can debulk or stabilize to open local control windows. Watch GI toxicity and myelosuppression.
—StandardCurated
High-dose Ifosfamide (salvage)
STS-standard salvage with occasional RMS responses; neuro/nephrotoxicity vigilance is essential. Consider when aiming to downstage for consolidative RT/surgery.
—StandardCurated
Doxorubicin/Dacarbazine (± Ifosfamide) (adult STS legacy)
Historic backbone with modest RMS activity; consider case-by-case when other regimens contraindicated. Cardio and marrow safety planning required.
—StandardCurated
Oral maintenance (vinorelbine + low-dose cyclophosphamide) (post-resp…
Exploratory disease-control concept after good response; adult RMS data limited—prefer on protocol.
MaintenanceStandardCurated
Targeted therapy
Anti-angiogenic TKIs (e
Anti-angiogenic TKIs (e.g., pazopanib) have limited RMS-specific data; reserve mainly for refractory settings or trials.
—StandardCurated
IGF1R/PI3K/AKT/mTOR: pathway alterations support trial eligibility
IGF1R/PI3K/AKT/mTOR: pathway alterations support trial eligibility; single-agent activity historically limited.
—StandardCurated
Hedgehog/GLI, MEK/ERK: investigational targets
Hedgehog/GLI, MEK/ERK: investigational targets; consider baskets.
—Guideline optionCurated
ctDNA/NGS
ctDNA/NGS can inform trial matching and detect resistance patterns.
—StandardCurated
NTRK fusion (rare): TRK inhibitors (tumor-agnostic)
NTRK fusion (rare): TRK inhibitors (tumor-agnostic) can be high-yield when present.
—StandardCurated
TFCP2-fusion subset: ALK overexpression
TFCP2-fusion subset: ALK overexpression—consider ALK-focused trials and keratin-positive RMS recognition.
—StandardCurated
FGFR4 activation/overexpression: trial-focused FGFR4 inhibitors and e…
FGFR4 activation/overexpression: trial-focused FGFR4 inhibitors and emerging CAR-T approaches.
—Guideline optionCurated
PAX–FOXO1 epigenetic dependency: BET/BRD4 inhibition trials and trans…
PAX–FOXO1 epigenetic dependency: BET/BRD4 inhibition trials and transcriptional-complex disruption strategies.
—StandardCurated
YAP/TEAD (Hippo dysregulation): early-phase TEAD inhibitor programs f…
YAP/TEAD (Hippo dysregulation): early-phase TEAD inhibitor programs for resistance/stemness biology.
—StandardCurated
p53–MDM2 axis: MDM2 antagonists in development—consider when TP53 wil…
p53–MDM2 axis: MDM2 antagonists in development—consider when TP53 wild-type and MDM2-high.
—StandardCurated
DDR targeting (PARP/ATR) as radiosensitizers/combos in refractory dis…
DDR targeting (PARP/ATR) as radiosensitizers/combos in refractory disease—trial contexts only.
—StandardCurated
Rational combos to blunt feedback (e.g., PI3K/mTOR + MEK)
Rational combos to blunt feedback (e.g., PI3K/mTOR + MEK) should be pursued in trials, not empirically off-label.
—Guideline optionCurated
Immunotherapy
MSI-H/dMMR (rare)
MSI-H/dMMR (rare): may enable PD-1 blockade under tumor-agnostic approvals.
—StandardCurated
Checkpoint inhibitors: modest activity overall
Checkpoint inhibitors: modest activity overall; combinations under study.
—Guideline optionCurated

Established care shown from OncoForge editorial curation · reviewed September 15, 2025 — authoritative citations (NCI PDQ / FDA) are being added.

Supportive care (12)
  • Pain management with multimodal analgesia; early palliative care involvement improves QoL.
  • Nutrition optimization to counter cachexia; involve oncology dietitian early.
  • Management of bowel obstruction risk and postoperative adhesions.
  • Psychosocial support and AYA-focused services when applicable.
  • Growth-factor support per regimen risk and prior cycle neutropenia to preserve dose intensity.
  • VTE prophylaxis/education individualized by surgery, immobilization, and TKI use; fast evaluation of leg swelling/SOB.
  • Fertility preservation consults (oocyte/embryo banking) before gonadotoxic therapy when feasible; discuss ovarian suppression limitations.
  • Cardio-oncology, nephrology, and pain/spine referrals early when organ-specific risks emerge.
  • Neuropathy prevention/rehab: dose adjustments, PT/OT for balance and fine-motor function.
  • Sleep, mood, and anxiety management—optimize antiemetics, pain plan, and behavioral supports to maintain resilience.
  • Vaccination review (avoid live vaccines on active chemo); prompt antiviral/antibacterial prophylaxis per risk.
  • Clear home plan for fever, dehydration, and port issues; provide direct lines and thresholds to avoid delays in care.
Investigational & adjunct compounds — detail (9)
Named in the literature
vincristine/doxorubicin/cyclophosphamidetotal abdominal radiotherapysurgeryRMS regimencomplete resectionchemotherapyradiationadriamycin
Lab / animal only
Actinomycin D

"Tested in people" rows show the highest trial phase found in that compound's cited human studies (Phase I–IV; "phase not reported" = a human study with no phase tag). "Studied" = named in the cited literature for this cancer. "FDA ✓" = FDA-approved for this cancer; "off-label" = an FDA-approved drug used outside its approved indications (per openFDA). Not a claim that anything works.

Living document — last change June 8, 2026: Cancer page updated.

Key points

  • Overview: Ovarian rhabdomyosarcoma is a very rare, aggressive ovarian malignancy with limited reported cases and no standardized treatment protocol. Reported cases span a wide age range, and the disease is often diagnosed at advanced stages.
  • Epidemiology: Ovarian rhabdomyosarcoma has been reported across a wide age range, with no clear childhood peak in one review. Published reviews describe only small numbers of cases worldwide and include both pediatric and adult patients.
  • Standard management: Reported management of ovarian rhabdomyosarcoma has generally involved multimodal care rather than surgery alone. Sources also describe staging and risk stratification, referral to specialized centers, and use of surgery, chemotherapy, and radiation in reported cases.
  • Prognosis: Reported outcomes for ovarian rhabdomyosarcoma are generally poor, with many series describing short survival after diagnosis or surgery. A few individual cases and small series reported longer event-free intervals after multimodal treatment.

9 sections — tap any heading to expand its cited detail. Key points are above.

OverviewOvarian rhabdomyosarcoma is a very rare, aggressive ovarian malignancy with limited reported cases and no standardized treatment protocol. Reported cases span a wide age range, and the disease is often diagnosed at advanced stages.9 points
  • Sources describe ovarian rhabdomyosarcoma as rare, and ovarian involvement by rhabdomyosarcoma as rare. [1]
  • Primary ovarian rhabdomyosarcoma has been reported as an extremely rare and aggressive malignancy with limited reported cases and no standardized treatment protocol. [2]
  • Sources describe ovarian rhabdomyosarcoma as often presenting at an advanced stage. [1]
  • The source states that rhabdomyosarcoma predominantly arises in parameningeal and periorbital regions and in other areas that do not typically contain striated muscle. [1]
  • A DICER1-mutated rhabdomyosarcoma of the ovary has been described as a rare, emerging entity with a predilection for the gynecologic and genitourinary tracts. [3]
  • Primary ovarian rhabdomyosarcoma is described as a rare ovarian neoplasm and as a very rare primary neoplasm of the ovary. [4][5]
  • Primary ovarian rhabdomyosarcomas are described as extremely rare in children. [6]
  • Sources report that primary ovarian rhabdomyosarcoma has been associated with teratomas and mixed mullerian tumors; cited case reports also describe ovarian immature teratoma with rhabdomyosarcomatous recurrence and a Sertoli-Leydig cell tumor with pleomorphic rhabdomyosarcoma. [4][7][8]
  • Reports describe ovarian rhabdomyosarcoma as having a poor prognosis. [8][7]
EpidemiologyOvarian rhabdomyosarcoma has been reported across a wide age range, with no clear childhood peak in one review. Published reviews describe only small numbers of cases worldwide and include both pediatric and adult patients.4 points
  • One review of 13 primary ovarian rhabdomyosarcoma cases reported ages from 7 to 79 years, and another review noted cases in a 60-year-old, a 13-year-old, and a 14-year-old. [9][10]
  • In a 13-case review, 11 tumors were embryonal and 2 were alveolar rhabdomyosarcomas. [11][9]
  • In the 13-case review, abdominal pain and swelling were reported presentations, tumor laterality included right ovary, left ovary, both ovaries, and unknown laterality, tumor stage ranged from stage I to stage IV, and tumor size ranged from 10 to 19.5 cm. [9]
  • One review reported that about 50% of cases were diagnosed with disease beyond the ovary. [5]
Key biomarkersReported biomarkers in ovarian rhabdomyosarcoma include serum enzyme elevations in some cases and several tumor molecular or immunohistochemical findings. Reported alterations include DICER1 mutations, myogenic marker positivity, and negative PAX-FOXO1 testing in one alveolar case.5 points
  • High serum CK-MB and LD-2 may serve as a marker of rhabdomyosarcoma, and one metastatic ovarian rhabdomyosarcoma case had increased serum creatine kinase, CK-MB, lactate dehydrogenase, and LD-2. [12]
  • The 2023 report described an ovarian DICER1-mutated rhabdomyosarcoma with two DICER1 mutations identified by sequencing. [3]
  • The sarcomatous component in the 2023 report was Myogenin and MYOD1 positive. [3]
  • DICER1 mutations have been reported in ovarian and fallopian tube embryonal rhabdomyosarcoma, and in one tubal case the mutation was germline while in the other two cases it was somatic. [10]
  • Rhabdomyoblastic differentiation in these tumors was positive for desmin, myogenin, and myoD1. [10]
Biology & pathwaysOvarian rhabdomyosarcoma has been discussed as arising in sites without striated muscle, with proposed origins from ovarian stromal fibroblasts or endometriotic stroma. Reported DICER1-mutated tumors can show mixed histologic elements, and molecular testing is needed for confirmation.10 points
  • The source states that rhabdomyosarcoma predominantly arises in parameningeal and periorbital regions and in other areas that do not typically contain striated muscle. [1]
  • The occurrence of ovarian rhabdomyosarcoma may be attributed to the presence of ovarian stromal fibroblasts or endometriotic stroma. [1]
  • DICER1-mutated ovarian rhabdomyosarcomas may show cartilage foci, teratoid mature glands, immature blastematous-like tubes, and/or neuroectodermal components. [3]
  • Molecular testing remains necessary to confirm the diagnosis of DICER1-mutated sarcomas. [3]
  • One review states that DICER1 mutations are associated with a variety of uncommon neoplasms including cervical and genitourinary embryonal rhabdomyosarcoma. [10]
  • One review states that ERMS arising at unusual sites, especially when they contain cartilage or bone/osteoid, are especially likely to be associated with DICER1 mutations. [10]
  • One case report described ovarian rhabdomyosarcoma arising from a prior endometrioma, with focal areas suggesting a possible underlying ovarian adenosarcoma with stromal overgrowth. [11]
  • One source states that rhabdomyogenesis recapitulates skeletal muscle differentiation during early fetal life. [5]
  • One source suggests rhabdomyoblasts in the ovary may arise from uncommitted stromal fibroblasts or fibroblasts of endometriotic stroma. [5]
  • One report states that the tumor recapitulates primitive embryonal testis and rhabdomyogenesis. [8]
Standard managementReported management of ovarian rhabdomyosarcoma has generally involved multimodal care rather than surgery alone. Sources also describe staging and risk stratification, referral to specialized centers, and use of surgery, chemotherapy, and radiation in reported cases.4 points
  • The source states that management requires a multimodal treatment approach; in this series, some patients also received abdominopelvic radiotherapy. [1]
  • Sarcomas should be treated in tertiary care centers with good pathology support and expertise. [13]
  • Surgery, chemotherapy, and radiation have been used in reported cases. [7][5]
  • One review states that aggressive combination therapy including surgery, radiation, and chemotherapy appears to be the only hope for improved survival. [5]
Treatments & compounds studiedThe section summarizes 14 therapeutics or procedures studied for ovarian rhabdomyosarcoma across chemotherapy, radiotherapy, surgery, and one nonspecific chemotherapy entry.8 treatments

Chemotherapy

  • vincristine/doxorubicin/cyclophosphamide: One pediatric report described chemotherapy including vincristine, doxorubicin, and cyclophosphamide with good response to therapy; the 2025 series says chemotherapy regimens were selected by risk stratification and aligned with international protocols, but does not name specific drugs or outcomes for those regimens. [1][6]
  • RMS regimen: One review described an excellent response to an RMS regimen in a young girl with ovarian rhabdomyosarcoma. [13]
  • chemotherapy: Chemotherapy was reported in case literature without a specific regimen being identified in the provided sources. [7][14][5]
  • adriamycin: Adriamycin was associated with a transient tumor response in one reported case. [14]

Radiotherapy

  • total abdominal radiotherapy: In the 2025 series, three patients received intensity-modulated abdominopelvic radiotherapy at a total dose of 2,400 cGy in 16 sessions. [1]
  • radiation: Radiation was reported in case literature. [7][5]

Procedures & devices

  • surgery: Reported surgical approaches included resection, unilateral oophorectomy or adnexectomy, ovarian-sparing staging, and primary cytoreduction. [1]
  • complete resection: Complete resection of the primary tumors before chemotherapy was described in one case report. [6]
Staging & riskOvarian rhabdomyosarcoma has been staged using IRSG criteria in reported series and case reports, with disease described across stages I to IV. Advanced-stage disease, including group IV or metastatic involvement, is commonly reported.4 points
  • The 2025 report says ovarian rhabdomyosarcoma often presents at an advanced stage; in its series, four of six patients were clinical stage and group IV due to distant metastases. [1]
  • The 2025 series also reported clinical group IV disease with metastatic involvement. [1]
  • One case report described metastatic spread to the splenic flexure of the colon and both lungs. [6]
  • In the 13-case review, tumors were reported across stages I to IV. [9]
PrognosisReported outcomes for ovarian rhabdomyosarcoma are generally poor, with many series describing short survival after diagnosis or surgery. A few individual cases and small series reported longer event-free intervals after multimodal treatment.5 points
  • Two pediatric cases were alive 8 and 9 months post-operatively after complete resection and chemotherapy. [6]
  • In the 13-case review, 7 of 11 patients with follow-up died of disease 10 days to 26 months after surgery, and 4 of 11 patients with follow-up were alive 2 to 9 months after surgery. [9]
  • One review reported survival ranging from 18 days to 15 months after diagnosis. [5]
  • One report states that prognosis is poor when rhabdomyosarcoma is a significant or predominant component of Sertoli-Leydig cell tumor. [8]
  • One case review concluded that prognosis is poor and similar to that of primary ovarian rhabdomyosarcoma when rhabdomyosarcomatous recurrence develops in ovarian immature teratoma. [7]
What we don't know yetOvarian rhabdomyosarcoma is so rare that its natural history, pathogenesis, and evidence base remain poorly defined. The literature also notes limited case numbers and a lack of standardized treatment approaches.6 points
  • Ovarian rhabdomyosarcoma is described as rare. [1]
  • The report describes a retrospective single-center analysis that included six patients. [1]
  • There is an urgent need for standardized therapeutic approaches to improve patient outcomes in ovarian RMS. [2]
  • Exact categorization of sarcoma is essential for an individualized approach. [13]
  • Pseudo-Meigs’ syndrome associated with primary rhabdomyosarcoma of the ovary had never been described to date. [15]
  • The literature discusses the pathogenesis of ovarian rhabdomyosarcoma. [8]

Sources

Every statement above is drawn from these reviewed sources. This page reports what they describe. Sources last checked June 8, 2026.

  1. Review articleOvarian Rhabdomyosarcoma in Children · 2025
  2. Case reportPrimary ovarian rhabdomyosarcoma: A diagnostic dilemma in an uncommon tumor · 2025
  3. Case reportDICER1-mutated rhabdomyosarcoma of the ovary with teratoid features · 2023
  4. Case reportPrimary ovarian rhabdomyosarcoma with heterologous elements: a case report · 2008
  5. Case reportRhabdomyosarcoma of the ovary: ultrastructural study of a case and review of literature · 1983
  6. Case reportPrimary ovarian rhabdomyosarcoma in children · 2008
  7. Case reportImmature teratoma of the ovary with a minor rhabdomyosarcomatous component and fatal rhabdomyosarcomatous metastases: the first case in a child · 2002
  8. Case reportOvarian Sertoli-Leydig cell tumor with rhabdomyosarcoma: an ultrastructural study · 1982
  9. Case reportPrimary ovarian rhabdomyosarcoma: a report of 13 cases · 1998
  10. Case reportEmbryonal Rhabdomyosarcoma of the Ovary and Fallopian Tube: Rare Neoplasms Associated With Germline and Somatic DICER1 Mutations · 2020
  11. Case reportEndometriosis Malignant Transformation Review: Rhabdomyosarcoma Arising From an Endometrioma · 2019
  12. Clinical trialIncreased activities of creatine kinase and lactate dehydrogenase isoenzymes in a patient with metastatic ovarian tumor · 1987
  13. Case reportPrimary rhabdomyosarcoma in ovary - Pathologist clinches it all · 2018
  14. Case reportImmature ovarian teratoma in a postmenopausal woman · 1987
  15. Case reportPrimary ovarian rhabdomyosarcoma coexisting with Pseudo-Meigs' syndrome in a young patient: a case report and brief literature review · 2020

What supports this page

The kinds of sources behind this page, strongest at the top. Faint rungs show what is not here yet.

Guideline
0
Meta-analysis
0
Systematic review
0
Randomized trial
0
Clinical trial
1
Observational
0
Case report
14
Review
3
Preclinical
0
Other
0

Evidence on specific compounds

How the published studies grade individual drugs, supplements, and other agents in Ovarian Rhabdomyosarcoma — each rated by how strong the evidence is, not a recommendation.

What recent studies report in Ovarian Rhabdomyosarcoma

These are reviewed studies whose abstracts concern Ovarian Rhabdomyosarcoma. Each describes only what that study reported. This is not a claim by OncoForge that any compound helps or harms Ovarian Rhabdomyosarcoma. Most are early lab, animal, or small human studies, and findings often conflict.

2 studiesTrial (1)

Tracking 2 published studies of Ovarian Rhabdomyosarcoma: 2 reviews/other.

Reported direction across studies: 1 positive, 1 inconclusive.

No human studies yet — these are preclinical (lab/animal) findings that may not translate to people.

These counts summarize what the studies reported; they are not a measure of whether anything works for Ovarian Rhabdomyosarcoma.

Compounds with studies mentioning Ovarian Rhabdomyosarcoma

Cyclophosphamide (2)Vincristine (2)Actinomycin d (1)Doxorubicin (1)
Case reportInconclusiveLimited evidenceTier 3 · early humann = 1

Primary ovarian rhabdomyosarcoma: A diagnostic dilemma in an uncommon tumor

Journal of cancer research and therapeutics · Oct 2025 · case report

CyclophosphamideActinomycin-dVincristineovarian rhabdomyosarcoma

This case report describes a 17-year-old girl with a very rare ovarian rhabdomyosarcoma. The tumor was diagnosed by imaging, pathology, and immunohistochemistry, and it came back within 3 months after surgery. The authors report that she then received VAC chemotherapy (vincristine, actinomycin D, and cyclophosphamide), and they emphasize the need for earlier diagnosis and more standardized treatment approaches.

Studied with: vincristine, actinomycin D, cyclophosphamide.

Key findings
  • Imaging showed a large solid-cystic pelvic mass.
  • Histopathology and immunohistochemical markers (desmin, myogenin, WT1) confirmed ovarian rhabdomyosarcoma.
  • Recurrence occurred within 3 months after surgical resection.
  • VAC chemotherapy was given after early relapse.
Limitations: Single-patient case report.; No control group.; No quantitative treatment outcome data reported.; Cannot determine effectiveness of VAC from this report alone.; Focus is diagnostic and descriptive rather than evaluative..

Describes a rare ovarian cancer case and subsequent chemotherapy, but does not evaluate a compound's anticancer effect in a comparative way.

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed

Case reportTrialReported positiveLimited evidenceTier 3 · early humann = 2

Primary ovarian rhabdomyosarcoma in children

Pediatric surgery international · May 2008 · case reports

CyclophosphamideVincristineDoxorubicinovarian rhabdomyosarcomaalveolar rhabdomyosarcomaembryonal rhabdomyosarcoma

This report describes two children with very rare primary ovarian rhabdomyosarcoma. After complete surgical removal, both received chemotherapy with vincristine, doxorubicin, and cyclophosphamide and had a good response. Both patients were alive 8 and 9 months after surgery.

Key findings
  • Two pediatric cases of primary ovarian rhabdomyosarcoma were described.
  • Both patients underwent complete resection of the primary tumor.
  • Both received vincristine, doxorubicin, and cyclophosphamide chemotherapy.
  • The abstract reports a good response to therapy and survival at 8 and 9 months post-operatively.
Limitations: Case report with only 2 patients.; No control group.; Short follow-up.; Cannot separate the effect of surgery from chemotherapy.; No dosing details reported..

Describes management of a rare ovarian cancer in children, including chemotherapy, but does not isolate the effect of any single compound.

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed

Browse all studies mentioning Ovarian Rhabdomyosarcoma →

Where the evidence is

What has been studied, and how strong it is, by topic. A dashed cell means no studies were found for that combination — a gap, not evidence of no effect. Open a row to see its studies.

CompoundHuman evidenceMechanismSafetyTrial
Cyclophosphamide—1—1
Vincristine—1—1
Actinomycin D—1——
Doxorubicin———1

Compounds with reported-positive results in Ovarian Rhabdomyosarcoma

Where at least one study reported a positive result, shown with the full picture, not just the wins. Positive results are more likely to be published, and most of these are early lab or animal studies that may not translate to people. This reports what studies found, not what works.

Preclinical only: lab / animal (3)
Limitations: Case report with only 2 patients.; No control group.; Short follow-up.; Cannot separate the effect of surgery from chemotherapy.; No dosing details reported..
Cited positive studies (1)
Vincristine1 positive
Limitations: Case report with only 2 patients.; No control group.; Short follow-up.; Cannot separate the effect of surgery from chemotherapy.; No dosing details reported..
Cited positive studies (1)
Doxorubicin1 positive
Limitations: Case report with only 2 patients.; No control group.; Short follow-up.; Cannot separate the effect of surgery from chemotherapy.; No dosing details reported..
Cited positive studies (1)

Evidence at a glance: compounds studied in Ovarian Rhabdomyosarcoma

A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.

CyclophosphamideInsufficient evidenceReported positive

No primary experimental studies yet.

Most authoritative study: Primary ovarian rhabdomyosarcoma: A diagnostic dilemma in an uncommon tumor

No human studies yet · No numeric effect sizes reported · All studies are small (n < 30).
VincristineInsufficient evidenceReported positive

No primary experimental studies yet.

Most authoritative study: Primary ovarian rhabdomyosarcoma: A diagnostic dilemma in an uncommon tumor

No human studies yet · No numeric effect sizes reported · All studies are small (n < 30).
Actinomycin DInsufficient evidenceInconclusive

No primary experimental studies yet.

Most authoritative study: Primary ovarian rhabdomyosarcoma: A diagnostic dilemma in an uncommon tumor

No human studies yet · No numeric effect sizes reported · Based on a single study.
DoxorubicinInsufficient evidenceReported positive

No primary experimental studies yet.

Most authoritative study: Primary ovarian rhabdomyosarcoma in children

No human studies yet · No numeric effect sizes reported · Based on a single study.

Clinical trials in Ovarian Rhabdomyosarcoma

Loading current trials from ClinicalTrials.gov… Search ClinicalTrials.gov →

Heading to an appointment? Get a printable one-page summary — studied compounds, open trials, interactions, and questions to ask.
Bring this to your appointment →

Go deeper

Questions to ask your oncologist

  • Which RMS subtype do I have (embryonal, alveolar, spindle/sclerosing, pleomorphic) and how does it change treatment?
  • Is fertility-sparing surgery possible and safe in my case?
  • Which chemo backbone is recommended for my age and subtype?
  • Do I need radiation for margin-positive or nodal disease?
  • Are there trials matched to my tumor’s drivers (e.g., PAX–FOXO1, PI3K/AKT/mTOR, MSI)?
  • Can we send tissue for RNA fusion panel and DNA NGS now, and again at progression to capture targets (e.g., TFCP2, FGFR4, ALK)?
  • Do we have enough banked tumor (FFPE + fresh-frozen) and a recent biopsy to qualify for molecular trials?
  • What is the plan if there’s inadequate response after 2–3 cycles—what are our pre-agreed switch criteria?
  • Am I a candidate for neoadjuvant therapy to improve the chance of an R0 resection?
  • If disease is limited, could metastasectomy, ablation, or SBRT consolidate a systemic response?
  • Would anthracycline cardioprotection (dexrazoxane) help preserve intensity without compromising efficacy?
  • Should we involve a sarcoma specialty center or enroll via a national consortium (SARC, EORTC, NCI)?
  • Are there basket trials for my biomarkers (FGFR4, ALK, NTRK, BET/BRD4, YAP/TEAD, MDM2)?
  • Could we combine targeted agents with RT or chemo on a protocol to blunt resistance feedback (e.g., PI3K/mTOR + MEK)?
  • What’s our VTE prevention plan and symptom-triggered pathway for urgent evaluation?
  • How will we monitor for cardiac, renal, and neurotoxicity, and what dose-modification rules protect outcomes?
  • Do I qualify for compassionate use / expanded access if a matched trial isn’t available?
  • Is there a role for ctDNA as an adjunct to imaging for trend-tracking in my case?

Find a trial

Search active and completed trials at these registries:

Citations

  1. WHO Classification of Tumors: Soft Tissue and Bone (RMS chapters)

    WHO/IARC

    • Subtypes and diagnostic criteria
    • Pathology markers and fusions

  2. PDQ® Childhood Rhabdomyosarcoma Treatment

    NCI

    • VAC-based regimens; RMS biology and staging concepts

  3. ESMO–EURACAN–GENTURIS Clinical Practice Guidelines: Soft Tissue and Visceral Sarcomas

    ESMO

    • Adult STS backbones (doxorubicin/ifosfamide; gemcitabine/docetaxel)
    • Radiation/local control principles

  4. Gynecologic tract rhabdomyosarcoma: clinicopathologic updates

    Peer-reviewed reviews/case series

    • Rarity and ovary-specific presentations
    • Patterns of spread and management nuances

  5. Ovarian Rhabdomyosarcoma in Children - PMC

    PubMed Central / Authors: M.G. Pérez et al.

    • Subtypes (embryonal most common, alveolar, pleomorphic, spindle cell/sclerosing)
    • Biomarkers (desmin, MyoD1, myogenin positive; negative for pancytokeratin, etc.)
    • Pathology (rare, from stromal fibroblasts/endometriotic stroma)
    • Treatment (surgery, chemotherapy like VAC, selective radiotherapy)
    • Prognosis (aggressive, multimodal improves outcomes)
    • Overview and rarity

  6. Molecular diagnostics in the management of rhabdomyosarcoma

    PubMed Central / Authors: M. Arnold et al.

    • Biomarkers (MYOD1 mutations, PAX3/7-FOXO1 fusions, RAS pathway mutations, NCOA2/VGLL2 fusions)
    • Subtypes and fusion-driven biology

  7. Embryonal rhabdomyosarcoma of the uterine corpus: a clinicopathologic study

    ScienceDirect / Authors: J.A. Bennett et al.

    • Biomarkers (desmin positive, myogenin and MyoD1 often focal positive)

  8. Myogenin is a Specific Marker for Rhabdomyosarcoma: An Immunohistochemical Study

    ResearchGate / Authors: G. Kumar et al.

    • Biomarkers (myogenin specific for RMS, desmin, MYOD1 define RMS)

  9. Rhabdomyosarcoma - BINASSS

    BINASSS / Authors: Various (review)

    • Biomarkers (desmin, myogenin, MyoD1 positive; spindle cell RMS fusions)

  10. Embryonal Rhabdomyosarcoma of the Ovary and Fallopian Tube: Rare Neoplasms Associated With Germline and Somatic DICER1 Mutations

    ResearchGate / Authors: W.G. McCluggage et al.

    • Biomarkers (DICER1 germline/somatic mutations in gynecologic RMS; some cases negative for desmin/myogenin/MyoD1 but atypical)

  11. Biological Role and Clinical Implications of MYOD1 L122R Mutation in Rhabdomyosarcoma

    MDPI / Authors: I. Szymczak et al.

    • Biomarkers (MYOD1 p.L122R mutation in spindle/sclerosing RMS, aggressive subset)

  12. Improving Individualized Rhabdomyosarcoma Prognosis Prediction: A Multimodal Machine Learning Approach

    medRxiv / Authors: L. Elouan et al.

    • Biomarkers (PAX3/PAX7-FOXO1 fusions as key prognostic markers)

  13. The Emerging Role and Clinical Significance of PI3K-Akt-mTOR in Rhabdomyosarcoma

    PubMed Central / Authors: Various (2025 Review)

    • Pathways (PI3K-Akt-mTOR hyperactivation, proliferation, survival, resistance)
    • Resistance (therapy pressure and network redundancy)

  14. Molecular Targets in Alveolar Rhabdomyosarcoma

    PubMed Central / Authors: Various

    • Pathways (PAX-FOXO1 transcriptional repression, interconnected mechanisms)

  15. Molecular and Cellular Biology of Rhabdomyosarcoma

    Wiley Online Library / Authors: Various (2015, updated references)

    • Pathways (FGF signaling, IGF1-R-PI3K-mTOR, ERK/MAPK)
    • Resistance (apoptosis prevention, cross-activation)

  16. Signaling Pathways that Overactivate Metabolism in Cancer

    JRPMS / Authors: Various

    • Pathways (PI3K/AKT/mTOR reprogramming glucose metabolism, tumor progression)

  17. Signaling Pathways in Rhabdomyosarcoma Invasion and Metastasis

    ResearchGate / Authors: Various

    • Pathways (PAX-FOXO1, IGF/RAS/MEK/ERK, PI3K/AKT/mTOR, cMET, FGFR4)
    • Resistance (parallel activation, RTK upregulation)

  18. Targeting the Hedgehog Pathway in Rhabdomyosarcoma

    MDPI / Authors: Various

    • Pathways (Hedgehog/GLI oncogenic role, stemness, proliferation)
    • Resistance (pathway bypass, limited monotherapy)

  19. Redox Biology in Rhabdomyosarcoma

    ScienceOpen / Authors: Various (2019)

    • Pathways (IGF1R, FGFR, EGFR leading to mTOR via PI3K/AKT)
    • Angiogenesis (VEGF involvement)

  20. Targeting Hedgehog and PI3K/AKT/mTOR in RMS

    Semantic Scholar / Authors: Geyer et al. (2018)

    • Pathways (PI3K/AKT/mTOR importance, regulation of HH signaling)
    • Resistance (feedback loops)

  21. PI3K/AKT/mTOR Pathway in Angiogenesis

    Frontiers / Authors: Various

    • Pathways (PI3K role in angiogenesis, normal/cancer tissues)

  22. Molecular Drivers of PAX3/7-FOXO1 Tumorigenesis

    BioMed Central / Authors: Various (2012)

    • Pathways (PAX-FOXO1 cooperating genes, target genes for tumorigenesis)

  23. Current Evidence and Directions for Intermittent Fasting During Chemotherapy

    PubMed Central / Authors: Various

    • Adjuncts (Fasting/FMD as adjunct to chemotherapy, safety, effects on nutritional status)

  24. Review of Under-Recognized Adjunctive Therapies for Cancer

    PubMed Central / Authors: Various

    • Adjuncts (Melatonin for circadian reset, sleep improvement in cancer)

  25. Review of Fasting-Mimicking Diets in Cancer Treatment

    News-Medical / Authors: Various (2024)

    • Adjuncts (Cyclic fasting/FMD role in cancer therapy, enhancing efficacy)

  26. Short-Term Fasting Synergizes with Solid Cancer Therapy

    MDPI / Authors: Various (2022)

    • Adjuncts (Fasting diets boosting antitumor immunity, synergizing with therapy)

  27. Fasting-Mimicking Diet in Patients Undergoing Active Cancer Treatment

    ClinicalTrials.gov / Authors: Various

    • Adjuncts (Pilot trial on 5-day FMD feasibility/safety during cancer treatment)

  28. Fasting Mimicking Diet May Be Safe, Effective as Adjunct to Chemo

    Cancer Network / Authors: Various (2020)

    • Adjuncts (FMD safe/effective adjunct to chemo, general oncology)

  29. Fasting and Fasting Mimicking Diets in Cancer Prevention and Therapy

    ScienceDirect / Authors: Various

    • Adjuncts (Fasting/FMD enhancing chemo, hormone therapy, immunotherapy)

  30. Fasting as Cancer Treatment: Myth or Breakthrough in Oncology

    Cureus / Authors: Various (2025)

    • Adjuncts (Fasting reducing tumor growth, enhancing chemo sensitivity)

  31. Immunomodulation after a Fasting Mimicking Diet Analyzed

    ASCO / Authors: Various

    • Adjuncts (FMD promoting CD8+ T-cell infiltration, decreasing Tregs)

  32. Therapeutic Fasting in Reducing Chemotherapy Side Effects

    MDPI / Authors: Various (2023)

    • Adjuncts (Fasting as adjunct to chemo, effects on side effects)

  33. Emergency Care for Ovarian Cancer: When to Call Your Doctor

    Not These Ovaries / Authors: Various (2025)

    • Red flags/Emergencies (Sudden chest pain, shortness of breath, fever during chemo, abdominal pain)
    • When to call (Persistent symptoms, dehydration)

  34. Ovarian Cancer Red Flags: Help Prevent Delayed Diagnosis

    PubMed / Authors: Various (2024)

    • Red flags (Unexplained abdominal lump, bloating, sterile urine samples)
    • When to call (Recurrent urinary symptoms, new IBS in >50s)

  35. Mode of Referral of Ovarian Cancer Patients

    PubMed Central / Authors: Various

    • Red flags (GPs/ED identifying symptoms for referral)

  36. Ovarian Cancer Red Flags: What to Know

    MDedge / Authors: Various (2024)

    • Red flags (Recurrent urinary symptoms, sterile urine)

  37. Rhabdomyosarcoma Stages and Risk Groups

    American Cancer Society / Authors: Various (2025)

    • Red flags (Metastasis assessment, bone marrow involvement)

  38. Referral to a Specialist for Symptoms of Ovarian Cancer

    Cancer Research UK / Authors: Various (2025)

    • Red flags (Unexplained abdominal lump, urgent referral)

  39. Ovarian Cancer Red Flags: Help Prevent Delayed Diagnosis

    ResearchGate / Authors: Various (2024)

    • Red flags (Symptoms warranting investigations, peritoneal signs)

  40. Ovarian Cancer Red Flags

    Target Ovarian Cancer / Authors: Various

    • Red flags (Sterile urine, new IBS >50s, abdominal girth increase)

  41. NCCN Guidelines for Patients: Ovarian Cancer

    NCCN / Authors: Various

    • Red flags/Emergencies (Abnormal blood counts, health issues signaling problems)

  42. Ovarian Cancer Staging

    OCRA / Authors: Various

    • Red flags (High-grade atypical cells, metastasis likelihood)

  43. Rhabdomyosarcoma: Current Therapy, Challenges, and Future Directions

    PubMed Central / Authors: Various

    • Complications (Surgical side effects, orbital RMS blindness)
    • Pathways/Adjuncts (General multimodal therapy)

  44. Molecular Review of Ovarian Rhabdomyosarcoma in Children

    PubMed / Authors: M.G. Pérez et al. (2025)

    • Overview (Rare, presents in young children, favorable site)

  45. Current and Future Treatment Strategies for Rhabdomyosarcoma

    Frontiers / Authors: Various

    • Adjuncts (Targeted therapies, multi-modality frontline)

  46. The Emerging Role of PI3K-Akt-mTOR in Rhabdomyosarcoma

    MDPI / Authors: Various

    • Pathways (PI3K-Akt-mTOR role, targeted therapies)

  47. Molecular Review of Rhabdomyosarcoma

    MalaCards / Authors: Various

    • Pathways (Molecular drivers in RMS)

  48. Case Report: Uterine Embryonal Rhabdomyosarcoma

    Frontiers / Authors: Various (2025)

    • Symptoms/Complications (Prolonged diagnostic process in gynecologic RMS)

  49. Signs and Symptoms of Rhabdomyosarcoma

    American Cancer Society / Authors: Various (2025)

    • Red flags (Lump/swelling, abdominal pain, dyspnea)

  50. Diagnosis and Treatment of Rhabdomyosarcomas

    Via Medica / Authors: Łomiak et al. (2023)

    • Symptoms (Head/neck, urogenital, abdominal presentations)

  51. Rhabdomyosarcoma: Symptoms, Prognosis & Treatment

    Cleveland Clinic / Authors: Various

    • Red flags (Nosebleeds, vomiting, lumps, similar to less serious conditions)

  52. Molecular Diagnostics in the Management of Rhabdomyosarcoma

    PubMed Central / Authors: M. Arnold et al.

    • Pathways (PAX3/7-FOXO1 fusions, FGFR4, MET, Hippo)
    • Resistance (Not explicitly, but network implications)

  53. Biological Role and Clinical Implications of MYOD1 L122R Mutation in Rhabdomyosarcoma

    MDPI / Authors: I. Szymczak et al.

    • Pathways (Myogenic transcriptional program, MYOD1 role in differentiation block, MYC-like activity)

  54. Childhood Rhabdomyosarcoma Treatment (PDQ®)

    National Cancer Institute / Authors: Various

    • Adjuncts (Chemotherapy regimens like VAC, radiation techniques, surgery)
    • Red flags/Emergencies (Metastatic complications, recurrence management)
    • Ovarian applicability (Genitourinary sites, conservative surgery)

  55. Evolving Classification of Rhabdomyosarcoma - PMC

    PubMed Central / Authors: Various (2023)

    • Subtypes (embryonal, alveolar, spindle/sclerosing, pleomorphic)
    • IHC (desmin+, MyoD1+, myogenin+)
    • Molecular (PAX3/7-FOXO1 fusions, MYOD1 mutations, TFCP2 fusions)

  56. Embryonal rhabdomyosarcoma - Pathology Outlines

    Pathology Outlines / Authors: Various (2025)

    • Histology (small round/spindle cells, rhabdomyoblastic differentiation)
    • IHC (desmin+, myogenin+, MyoD1+; negative cytokeratin/EMA)
    • Molecular (no FOXO1 fusion in embryonal; high Ki-67)

  57. Fusion-driven Spindle Cell Rhabdomyosarcomas of Bone and Soft Tissue

    Modern Pathology / Authors: Various (2023)

    • Molecular (TFCP2 fusions with ALK expression, desmin/MyoD1+)
    • Subtypes (spindle cell RMS)
    • IHC (ALK+, keratin+ in TFCP2 cases)

  58. Identification of FGFR4-activating Mutations in Human Rhabdomyosarcomas

    PubMed / Authors: Various (2009)

    • Molecular (FGFR4 mutations N535/V550 activating, frequent in alveolar RMS)
    • Translational (oncogene function, trial targets)

  59. Embryonal Rhabdomyosarcoma of the Uterine Corpus: Molecular Analysis Highlighting DICER1 Association

    ScienceDirect / Authors: J.A. Bennett et al. (2023)

    • Molecular (DICER1 alterations in gynecologic RMS)
    • IHC (variable myogenin/MyoD1)
    • Clinical (re-biopsy, trial triage)

FAQs

Is CA-125 useful in ovarian rhabdomyosarcoma?
  • Generally no. CA-125 tracks epithelial ovarian carcinoma; RMS lacks reliable serum markers. Monitoring relies on symptoms and imaging.
Which chemo backbones are typical?
  • Pediatric/AYA: VAC-based regimens (vincristine, actinomycin, cyclophosphamide) with risk-adapted additions. Adults: anthracycline/ifosfamide or gemcitabine/docetaxel are common STS backbones; choices individualize to histology, stage, and tolerance.
Is fertility-sparing surgery possible?
  • Occasionally in strictly unilateral, early disease with careful staging and pediatric/AYA considerations. Most adults require oophorectomy; decisions are individualized.
Does immunotherapy help?
  • RMS responsiveness to single-agent PD-1 is limited; benefit is more likely with MSI-H/dMMR (rare) or in trials using combinations.
Should we pursue genetic testing?
  • Yes—tumor NGS for fusions (e.g., PAX–FOXO1) and other alterations; consider germline testing if syndromic features (e.g., DICER1) or family history.
How often should imaging be done during treatment?
  • Commonly every 6–12 weeks during active therapy, faster if symptoms change or trial protocol dictates. Use the same modalities over time to compare response consistently.
Is ctDNA useful for RMS follow-up?
  • Sensitivity is limited in sarcomas; bespoke assays can help in select cases but imaging remains the primary tool. Consider ctDNA as adjunctive, not decisive.
When should we re-biopsy?
  • At progression or when biology may change management—e.g., to confirm RMS component in carcinosarcoma recurrence, to look for targetable fusions/mutations, or to enroll on a molecular trial.
What trial keywords should we search for adults with RMS?
  • Adult rhabdomyosarcoma; fusion-positive PAX3/7–FOXO1; TFCP2 fusion; FGFR4; ALK; YAP/TEAD; BET/BRD4; MDM2; sarcoma basket; immunotherapy combinations.
When do we change therapy for lack of response?
  • If clear radiologic progression, symptomatic worsening, or failure to achieve disease control after an adequate trial (usually 2–3 cycles) and adherence confirmed.
Is there a role for radiation?
  • Yes—local control (post-op margins, unresectable primaries), palliation of painful bone mets, and control of oligoprogression. Coordinate fields with systemic therapy timing.
Can local therapies help liver or bone lesions?
  • In selected cases, ablation/embolization (liver) or stereotactic/targeted radiation (bone/spine) can add control or palliation. Consider case-by-case in tumor board.
How do we manage high VTE risk?
  • Low threshold to evaluate unilateral leg swelling or chest symptoms. Prophylaxis is individualized; balance bleeding risk, surgery timing, and any anti-angiogenic agents.
What about anti-angiogenic agents (e.g., pazopanib) in adult RMS?
  • Evidence is stronger in non-RMS STS; RMS data are limited. Consider mainly in refractory settings or trials; watch wound-healing and hypertension risks.
How do we protect the heart with anthracyclines?
  • Baseline and periodic ECHO/MUGA; manage CV risk factors; consider dexrazoxane when cumulative doses rise or in higher-risk patients per guidelines.
How do we prevent chemo delays from neutropenia?
  • Primary G-CSF prophylaxis for high-risk regimens, prompt fever workups, and growth-factor support per regimen risk and prior cycle history.
What labs and symptoms should we track at home?
  • CBC/CMP per cycle; monitor fever, SOB, chest/leg pain, new neuro deficits, urine output, RUQ pain/jaundice, escalating bone/spine pain, and port changes.
Any special considerations with ureteral stents?
  • Watch for flank pain, fever, or reduced output (possible obstruction/infection). Coordinate stent exchanges around chemo cycles when feasible.
How does having a carcinosarcoma with RMS differentiation change management?
  • It confirms a biphasic tumor; systemic therapy is often guided by the dominant/aggressive component and stage. Re-sampling at progression can clarify the biology driving relapse.
Are off-label or repurposed agents worth exploring?
  • Discuss risks/benefits with the team. Prioritize agents with plausible biology and safety, and consider enrolling in trials to access combinations with oversight.
What supportive care moves the needle the most?
  • Early nutrition/hydration planning, aggressive antiemetics/mucositis care, neuropathy prevention tactics, DVT awareness, physical conditioning, and symptom-triggered rapid access.
What signals possible spinal cord compression?
  • New back pain with leg weakness/numbness, gait changes, or bladder/bowel dysfunction—this is an emergency; contact the team or go to the ED immediately.

What we don't know yet

  • No randomized trials specific to primary ovarian RMS.
  • Heterogeneous histology across small case series.
  • Limited prospective data on adult RMS regimens in ovarian site.
  • Unclear role of immunotherapy outside biomarker-selected trials.
  • Comparative effectiveness of pediatric VAC-like vs adult STS backbones in adults with ovarian RMS.
  • Optimal sequencing of surgery ↔ neoadjuvant/adjuvant therapy to maximize R0 rates.
  • Defined indications/dosing for pelvic RT and nodal fields specific to ovarian RMS.
  • Prospective value of ctDNA/MRD assays for response-adapted switches.
  • Real-world outcomes of ALK/FGFR4/BET/TEAD/MDM2 targeted approaches in RMS subsets.
  • Best criteria for oligometastatic consolidation (SBRT/ablation/metastasectomy) in potential cure pathways.
  • Fertility-sparing oncologic safety data in very early unilateral disease.